This is a treatment option for hepatocellular carcinoma, the most common type of liver cancer. You would only have this treatment for small tumours and if you can’t have other treatments. For example, ...
An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk ...
In December, Detroit-based Barbara Ann Karmanos Cancer Center became the first facility in the world to offer at-home liver cancer treatment with the TheraBionic P1, a device recently approved by ...
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...
it could be an innovative approach to the prevention and treatment of liver cancer. It is unclear whether there are similar guardians in other organs. Moritz Mall and Judith Zaugg are convinced ...
Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of Roche ...
Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback